Taken together, we have for the first time demonstrated that HDACIs inhibit the viability of gallbladder carcinoma cells in a dose- and time-dependent manner and cause G1 phase arrest of the cell cycle by suppressing AKT/mTOR signaling. The gene discussed is AKT1; the disease is gallbladder carcinoma.